A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventions

DRUG: Aficamten
DRUG: Placebo

Sponsor

Cytokinetics